Table 1.
Statistical table
| Figure | Data structure |
Type of test |
Sample size | Statistical data |
|---|---|---|---|---|
| 1A Cocaine administration in activity boxes with no habituation (PICK1 KO and WT mice) | Normal distribution | Two-way ANOVA followed by Holm–Sidak multiple comparison | WT:0 =145 = 1110 = 1230 = 12KO:0 = 125 = 1110 = 1130 = 11 | Interaction:p = 0.32, F(3,87) = 1.88Treatment:p ≤ 0.0001, F(3,87) = 17.5Genotype:p = 0.0002, F(1,87) = 14.91Multiple comparison, Treatment, df = 87:WT (compared to saline):5: p = 0.35, t = 0.9310: p = 0.002, t = 3.4130: p ≤ 0.0001, t = 6.15KO (compared to saline):5: p = 0.81, t = 0.2410: p = 0.36, t = 1.2830: p = 0.003, t = 3.45Multiple comparison, Genotype, df = 87:Saline: p = 0.45, t = 0.765: p = 0.34, t = 1.3210: p = 0.03, t = 2.5930: p = 0.02, t = 2.97 |
| 1B–DCocaine administration in open field after a 120-min habituation (PICK1 KO and WT mice); drug comparison of 60 min before and after administration | Normal distribution | Three-way ANOVA of injection (last 60 min of habituation vs first 60 min of drug primed), genotype (WT vs KO), andtreatment (0- vs 10- vs 30-mg/kg cocaine)followed by t test(SPSS statistics) | WT:0 = 510 = 930 = 8KO:0 = 510 = 1030 = 10 | Injection: p < 0.0001, F = 131.69, df = 1Genotype: p = 0.048, F = 4.16, df = 1Treatment: p < 0.0001, F = 14.24, df = 2Genotype*treatment: p = 0.21, F = 1.62, df = 2t test:Genotype effect after drug administration:Saline: p = 0.732, t = -0.355, df = 810: p = 0.01, t = 2.87, df = 1730: p = 0.44, t = 0.821, df = 16 |
| 2A Sensitization overview | NA | NA | NA | NA |
| 2B Cocaine sensitization of WT mice | Normal distribution | Three-way ANOVA(SPSS statistics) | Saline:n = 9Cocaine:n = 11 | Sensitization (day 1 vs 6)Day: p = 0.04, F = 4.61, df= 1Day*genotype: p = 0.72, F = 0.13, df = 1Day*treatment: p < 0.0001, F = 28.73, df = 1Day*genotype*treatment: p = 0.79, F = 0.07, df = 1Maintenance of sensitization (day 6 vs 12 vs 20)Day: p = 0.01, F = 5.13, df = 2Day*genotype: p = 0.46, F = 5.13, df = 2Day*treatment: p = 0.01, F = 5.32, df = 2Day*genotype*treatment: p = 0.71, F = 0.35, df = 2 |
| 2C Self-administration with cocaine | Normal distribution | Two-way ANOVA | WT:n = 7KO:n = 9 | Interaction:p = 0.61, F(4,70) = 0.68Cocaine doses:p = 0.0009, F(4,70) = 5.28Genotype:p = 0.04, F(1,70) = 4.46 |
| 2D Self-administration with liquid food | Normal distribution | Two-way ANOVA | WT:n = 9KO:n = 10 | Interaction:p = 0.87, F(4,85) = 0.30Food concentration:p < 0.0001, F(4,85) = 18.82Genotype:p = 0.43, F(1,85) = 0.63 |
| 3A–C SKF administration in open field after a 120-min habituation (PICK1 KO and WT mice); drug comparison of 60 min before and after administration | Normal distribution | Three-way ANOVA of injection (last 60 min of habituation vs first 60 min of drug primed), genotype (WT vs KO), andtreatment (0- vs 0.1- vs 1-mg/kg cocaine)followed by t test(SPSS statistics) | WT:0 = 50.3 = 81 = 8KO:0 = 50.3 = 91 = 8 | Injection: p < 0.0001, F = 341.98, df = 1Genotype: p = 0.22, F = 1.58, df = 1Treatment: p < 0.0001, F = 21.15, df = 2Genotype*treatment: p = 0.75, F = 0.29, df = 2 |
| 3D–F Quinpirole administration in open field after a 120-min habituation (PICK1 KO and WT mice); drug comparison of 60 min before and after administration | Normal distribution | Three-way ANOVA of injection (last 60 min of habituation vs first 60 min of drug primed), genotype (WT vs KO), andtreatment (0- vs 0.1- vs 10- mg/kg cocaine)followed by t test (SPSS statistics) | WT:0 = 60.1 = 910 = 10KO:0 = 70.1 = 1010 = 8 | Injection: p < 0.0001, F = 170.29, df = 1Genotype: p = 0.81, F = 0.06, df = 1Treatment: p = 0.44, F = 0.83, df = 2Genotype*treatment: p = 0.45, F = 0.83, df = 2 |
| 3G Surface levels of D1R | Normal distribution | One-sample t test | WT:n = 4KO:n = 5 | p = 0.13 (two tailed), t = 1.91, df = 4 |
| 3H Striatal CREB protein levels | Normal distribution | One-sample t test | WT:n = 8KO:n = 8 | p = 0.61 (two tailed), t = 0.53, df = 7 |
| 3I Striatal p-CREB protein levels | One-sample t test | WT:n = 4KO:n = 4 | p = 0.98 (two tailed), t = 0.03, df = 3 | |
| 4A Vmax of synaptosomal DA uptake in WT vs PICK1 KO mice | Assuming normality | Unpaired t test | WT:n = 3KO:n = 3 | Vmax: p = 0.025 (two tailed), t = 3.48, df = 4Km: p = 0.23 (two tailed), t = 1.43, df = 4 |
| 4B Saturation curve of synaptosomal DA uptake in WT vs PICK1 KO mice | NA | NA | NA | NA |
| 4C Surface levels of DAT | Assuming normality | One-sample t test | WT:n = 4KO:n = 4 | p = 0.39 (two tailed), t = 1.01, df = 3 |
| 4D Sucrose gradient showing DAT distribution | Assuming normality | One-sample t test | WT:n = 3KO:n = 3 | p = 0.36 (two tailed), t = 1.18, df = 2 |
| 4E Vmax of synaptosomal DA uptake in WT vs DAT + Ala mice | Assuming normality | Unpaired t test | WT:n = 4KO:n = 4 | Vmax: p = 0.03 (two tailed), t = 2.74, df = 6Km: p = 0.04 (two tailed), t = 2.67, df = 6 |
| 4F Saturation curve of synaptosomal DA uptake in WT vs DAT + Ala mice | NA | NA | NA | NA |
| 4G Cocaine administration in activity boxes with no habituation (DAT + Ala and WT mice) | Normal distribution | Two-way ANOVA followed by Holm–Sidak multiple comparison | WT:0 =95 = 810 = 1030 = 11KO:0 = 125 = 1110 = 1130 = 10 | Interaction:p = 0.48, F(3,74) = 0.84Treatment:p ≤ 0.0001, F(3,74) = 20.31Genotype:p = 0.99, F(1,74) = 4.810e-005Multiple comparison, Treatment, df = 74:WT (compared to saline):5: p = 0.12, t = 1.5610: p = 0.003, t = 3.2530: p ≤ 0.0001, t = 5.97KO (compared to saline):5: p = 0.03, t = 2.510: p = 0.03, t = 2.4130: p < 0.0001, t = 4.91Multiple comparison, Genotype, df = 74:Saline: p = 0.76, t = 0.445: p = 0.76, t = 1.0410: p = 0.76, t = 0.6730: p = 0.76, t = 0.89 |
| 5A Striatal DA levels measured by HPLC analysis | Normal distribution | Unpaired t test | WT:n = 7KO:n = 7 | p = 0.01, t = 3.02, df = 12 |
| 5B Peak amplitude of KCl-evoked DA release | Normal distribution | Unpaired t test | WT:n = 5KO:n = 7 | p = 0.04, t = 2.35, df = 10 |
| 5C Trace of peak amplitude of KCl-evoked DA release | NA | NA | NA | NA |
| 5D Striatal VMAT2 protein levels | Normal distribution | One-sample t test | WT:n = 6KO:n = 6 | p = 0.54, t = 0.66, df = 5 |
| 5E Striatal TH protein levels | Normal distribution | One-sample t test | WT:n = 10KO:n = 10 | p = 0.008, t = 3.38, df = 9 |
| 5F Striatal pTH protein levels | Assuming normality | One-sample t test | WT:n = 3KO:n = 3 | p = 0.38, t = 1.12, df = 2 |
| 5G Midbrain TH protein levels | Normal distribution | One-sample t test | WT:n = 8KO:n = 8 | p = 0.92, t = 0.1, df = 7 |
| 5H Midbrain pTH protein levels | Assuming normality | One-sample t test | WT:n = 3KO:n = 3 | p = 0.46, t = 0.90, df = 2 |
| 5I Midbrain TH mRNA levels | Assuming normality | One-sample t test | WT:n = 3KO:n = 3 | p = 0.89, t = 0.16, df = 2 |
| 6A Midbrain IHC staining of TH and PICK1 | NA | NA | WT:n = 3KO:n = 1 | NA |
| 6B Fluorescence polarization assay of TH-PICK1 binding | NA | NA | Six technical replicates from two individual experiments | NA |
| 6C Coimmunoprecipitation of TH and PICK1 in striatum and midbrain | NA | NA | Three in each group | NA |
| 6D Staining of GFP + TH + PICK1 following PICK1 KD in rat dopaminergic neurons | NA | NA | WT:n = 40KO:n = 40from two dissections, three transductions | NA |
| 6E TH levels following PICK1 KD in rat dopaminergic neurons | Normal distribution | Unpaired t test | WT:n = 40KO:n = 40From two dissections, three transductions | p = 0.009, t = 2.68, df = 78 |
| 6F PICK1 levels following PICK1 KD in rat dopaminergic neurons | Non-normal | Mann–Whitney test | WT:n = 40KO:n = 40from two dissections, three transductions | p < 0.0001 |